Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fengliao Changweikang Keli in IBS-D
NCT07061184Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fengliao changweikang in Irritable bowel syndrome with diarrhea (IBS-D) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: IBS Severity Scoring System at 36 weeks. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
fengliao changweikang
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT07061184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061184.